Literature DB >> 21166002

Radiofrequency ablation of colorectal hepatic metastases.

Jeffrey P Guenette1, Damian E Dupuy.   

Abstract

Radiofrequency ablation (RFA) may be performed intraoperatively, laparoscopically, or percutaneously. The percutaneous approach is associated with the least procedural risk and may be performed under local anesthesia. Percutaneous RFA should be considered a primary treatment option for patients with unresectable hepatic tumors or conditions that prohibit general anesthesia or abdominal surgery. Continually improving thermal ablation and imaging technologies are likely to further increase tumor ablation efficacy and expand its role in treatment of hepatic metastases.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21166002     DOI: 10.1002/jso.21658

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

Review 1.  Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation.

Authors:  Muneeb Ahmed; Marwan Moussa; S Nahum Goldberg
Journal:  Chem Phys Lipids       Date:  2011-12-14       Impact factor: 3.329

2.  Colorectal cancer and 18FDG-PET/CT: what about adding the T to the N parameter in loco-regional staging?

Authors:  Pier Paolo Mainenti; Delfina Iodice; Sabrina Segreto; Giovanni Storto; Mario Magliulo; Giovanni Domenico De Palma; Marco Salvatore; Leonardo Pace
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

3.  Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center.

Authors:  Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous
Journal:  Radiology       Date:  2015-08-12       Impact factor: 11.105

4.  Thermal ablation of unresectable liver tumors: factors associated with partial ablation and the impact on long-term survival.

Authors:  Philipp Wiggermann; Ralf Puls; Andrej Vasilj; Dominik Sieroń; Andreas G Schreyer; Ernst-Michael Jung; Wojciech Wawrzynek; Christian Stroszczynski
Journal:  Med Sci Monit       Date:  2012-02

5.  Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases.

Authors:  Christian Wybranski; Martin Zeile; David Löwenthal; Frank Fischbach; Maciej Pech; Friedrich-Wilhelm Röhl; Günther Gademann; Jens Ricke; Oliver Dudeck
Journal:  Radiat Oncol       Date:  2011-04-27       Impact factor: 3.481

Review 6.  More than just tumor destruction: immunomodulation by thermal ablation of cancer.

Authors:  Sebastian P Haen; Philippe L Pereira; Helmut R Salih; Hans-Georg Rammensee; Cécile Gouttefangeas
Journal:  Clin Dev Immunol       Date:  2011-12-29

7.  Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases (LAVA): study protocol for a randomised controlled trial.

Authors:  Kurinchi Gurusamy; Neil Corrigan; Julie Croft; Maureen Twiddy; Stephen Morris; Nick Woodward; Steve Bandula; Daniel Hochhauser; Vicky Napp; Alison Pullan; Nicholas Jakowiw; Raj Prasad; Steven Olde Damink; C J H M van Laarhoven; Johannes H W de Wilt; Julia Brown; Brian R Davidson
Journal:  Trials       Date:  2018-02-13       Impact factor: 2.279

8.  Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases​.

Authors:  Craig Meiers; Amy Taylor; Brian Geller; Beau Toskich
Journal:  J Gastrointest Oncol       Date:  2018-04

9.  Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.

Authors:  Tetsuhide Ito; Takuji Okusaka; Masafumi Ikeda; Hisato Igarashi; Chigusa Morizane; Kohei Nakachi; Takeshi Tajima; Akio Kasuga; Yoshie Fujita; Junji Furuse
Journal:  Jpn J Clin Oncol       Date:  2012-07-31       Impact factor: 3.019

10.  IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment.

Authors:  Mario Catarinella; Andrea Monestiroli; Giulia Escobar; Amleto Fiocchi; Ngoc Lan Tran; Roberto Aiolfi; Paolo Marra; Antonio Esposito; Federica Cipriani; Luca Aldrighetti; Matteo Iannacone; Luigi Naldini; Luca G Guidotti; Giovanni Sitia
Journal:  EMBO Mol Med       Date:  2016-02-01       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.